Clinical Trial Detail

NCT ID NCT03264066
Title A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

renal cell carcinoma

transitional cell carcinoma

head and neck squamous cell carcinoma

Therapies

Atezolizumab + Cabozantinib

Age Groups: adult senior

No variant requirements are available.